Skip to content

Author

O. Mironenko

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Mythologization of statistics in biomedical research

Reproducibility of scientific research has become a major concern in recent years. Inappropriate application of statistical analysis methods by researchers is considered one of the causes of the reproducibility crisis. Drawing on the concept of "statistical myths" – persistent, recurring distortions of statistical conc...

M. Slavenko, O. Mironenko, M. Kuznetsov et al. · 0 citations
Review Open access Aug 2026

Comparative efficacy and safety of prolgolimab and nivolumab in first-line therapy for metastatic or unresectable melanoma: a systematic review, matching-adjusted indirect comparison, and cost-effectiveness analysis

Background . Metastatic and unresectable cutaneous melanoma (MM/uRCM) is an aggressive malignancy associated with high mortality due to its pronounced metastatic potential. Immune checkpoint inhibitors are used to treat MM/uRCM in the Russian Federation. These inhibitors include nivolumab and prolgolimab, which...

I. Utyashev, I. Myslevtsev, O. Mironenko et al. · 0 citations
Aug 2026

[Comparison of 6-Year Outcomes after Open Surgery, Successful Laparoscopic Adhesiolysis, and Non-Operative Management of Adhesive Small Bowel Obstruction].

Six-year survival of patients with SBO was better after NOM and LA compared to OS, and mean total hospital-stay over 6 years was significantly shorter after LA and NOM compared to OS, while MLE did not differ significantly between the LA and NOM groups.

A. Tyagunov, B. Abdulkarim, O. Mironenko et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.